Creon 10.000

Primær information

  • Handelsnavn:
  • Creon 10.000 Lipase 10.000 EP-e enterokapsler, hårde
  • Dosering:
  • Lipase 10.000 EP-e
  • Lægemiddelform:
  • enterokapsler, hårde
  • Brugt til:
  • Mennesker
  • Medicin typen:
  • Allopatiske stof

Dokumenter

Lokation

  • Fås i:
  • Creon 10.000 Lipase 10.000 EP-e enterokapsler, hårde
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • Lægemiddelstyrelsen - Danish Medicines Agency
  • Autorisation status:
  • Markedsført
  • Autorisationsnummer:
  • 11837
  • Sidste ændring:
  • 16-07-2018

Indlægsseddel: sammensætning, indikationer, bivirkninger, dosering, interaktioner, bivirkninger, graviditet, amning

Ô:- ¼»²²» ·²º±®³¿¬·±² ¹±¼¬ ·¹»²²»³ô º(® ¼« ¾»¹§²¼»® ¿¬ ¬¿¹» ³»¼·½·²»²ò

Ü« µ¿² º; ¼»²²» ³»¼·½·² «¼»² ®»½»°¬ò Ú±® ¿¬ ±°²; ¼»² ¾»¼-¬» ª·®µ²·²¹ô -µ¿´ ¼«

¿´¬·¼ º(´¹» ª»¶´»¼²·²¹»®²» · ¼»²²» ·²º±®³¿¬·±²ò

Ù»³ ·²º±®³¿¬·±²»²ò Ü« º;® ³;-µ» ¾®«¹ º±® ¿¬ ´:-» ¼»² ·¹»²ò

H²-µ»® ¼« ³»®» ·²º±®³¿¬·±²ô -; µ±²¬¿µ¬ ´:¹» »´´»® ¿°±¬»µò

ïò Ê×ÎÕÒ×ÒÙ ÑÙ ßÒÊÛÒÜÛÔÍÛ

Ý®»±² ïðòððð »® ¾®«²»ñµ´¿®» µ¿°-´»®ô ¼»® ·²¼»¸±´»® »¬ ¹®¿²«´¿¬ ¾»-¬;»²¼» ¿º

º±®¼(¶»´-»-»²¦§³»®ò

Ý®»±² ïðòððð »²¬»®±µ¿°-´»® ·²¼»¸±´¼»® º±®¼(¶»´-»-»²¦§³»®ô -±³ º®»³³»®

º±®¼(¶»´-»²ò Ü« µ¿² ¬¿¹» Ý®»±² ïðòðð𠪻¼ -§¹¼±³³» · ¾«¹-°§¬µ·®¬´»²ò

Ô:¹»²

µ¿²

¸¿ª»

º±®»-µ®»ª»¬

»²

¿²¼»²

¿²ª»²¼»´-»ò

Ú(´¹

¿´¬·¼

´:¹»²-

¿²ª·-²·²¹ò

îò Ê×ÙÌ×Ù ×ÒÚÑÎÓßÌ×ÑÒ ÍÑÓ ÜË ÍÕßÔ ÔZÍÛô ÚHÎ ÜË ÌßÙÛÎ ÝÎÛÑÒ ïðòððð

Ì¿¹ ·µµ» Ý®»±² ïðòððð »²¬»®±µ¿°-´»® ¸ª·-æ

·²¼¸±´¼--¬±ºº»® · Ý®»±² ïðòðððò

Ü« »® ¿´´»®¹·-µ ±ª»® º±® -ª·²»°®±¬»·² »´´»® ¿²¼®» -ª·²»°®±¼«µ¬»®ò

Ü« ¸¿® ¿µ«¬ ¾»¬:²¼»´-» · ¾«¹-°§¬µ·®¬´»²ò

Ü« ¸¿® ¿µ«¬ º±®ª:®®·²¹ ¿º µ®±²·-µ ´·¼»´-» · ¾«¹-°§¬µ·®¬´»²ò

Í:®´·¹» º±®¸±´¼-®»¹´»®æ

Ü« -µ¿´ µ±²¬¿µ¬» ´:¹»²ô ¸ª·-æ

Ü« ¸¿® -ª:® º±®-¬±°°»´-»ô

¬¿®³»² ·µµ» º«²¹»®»®ô »´´»®

¼»® »® ¾»¬:²¼»´-» · ¬¿®³»²ò

¿²ª·-²·²¹ò

Þ®«¹ ¿º Ý®»±² ïðòððð -¿³³»² ³»¼ ³¿¼ ±¹ ¼®·µµ»ª¿®»®

Ü»¬ »® ¾»¼-¬ ¿¬ ¬¿¹» Ý®»±² ïðòððð -¿³³»² ³»¼ ³¿¼ ±¹ ¼®·µµ»ò

Ù®¿ª·¼·¬»¬ ±¹ ¿³²·²¹

Ú; ª»¶´»¼²·²¹ ¸±- ´:¹»² »´´»® °; ¿°±¬»µ»¬ º(® ¼« ¬¿¹»® ²±¹»² º±®³ º±®

³»¼·½·²ò

Ù®¿ª·¼·¬»¬æ

Ü« ³; µ«² ¬¿¹» Ý®»±² ïðòððð »²¬»®±µ¿°-´»® »º¬»® ´:¹»²- ¿²ª·-²·²¹ò

ß³²·²¹æ

Ü« µ¿² ¿³³»ô -»´ª±³ ¼« ¬¿¹»® Ý®»±² ïðòðððò

µ ±¹ ¿®¾»¶¼--·µµ»®¸»¼

Ý®»±² ïðòððð °;ª·®µ»® ·µµ» ¿®¾»¶¼--·µµ»®¸»¼»² »´´»® »ª²»² ¬·´ ¿¬ º:®¼»- -·µµ»®¬

Þ®«¹ ¿º ¿²¼»² ³»¼·½·²

Ú±®¬:´ ¿´¬·¼ ´:¹»² »´´»® ¿°±¬»µ»¬ô ¸ª·- ¼« ¾®«¹»® ¿²¼»² ³»¼·½·² »´´»® ¸¿® ¾®«¹¬ ¼»¬

º±® ²§´·¹ò Ü»¬ ¹:´¼»® ±¹-; º±® ³»¼·½·²ô -±³ ·µµ» »® °; ®»½»°¬ô ³»¼·½·² -±³ »® µ(¾¬

· «¼´¿²¼»¬ô ²¿¬«®´:¹»³·¼´»® -¿³¬ -¬:®µ» ª·¬¿³·²»® ±¹ ³·²»®¿´»®ò

íò Í[ÜßÒ ÍÕßÔ ÜË ÌßÙÛ ÝÎÛÑÒ ïðòððð

ܱ-»®·²¹

ʱµ-²»æ ïŠ î »²¬»®±µ¿°-´»® ¬·´ ¸±ª»¼³;´¬·¼»®²»ò

Þ»¸¿²¼´·²¹»² -¬¿®¬»® ³»¼ ´¿ª ¼±-·- ±¹ ¾´·ª»® ¼»®»º¬»® ¶«-¬»®»¬ ¬·´ ¼·¬ ¾»¸±ªò Ü«

³; µ«² :²¼®» ¼·² ¼±-·- · -¿³®;¼ ³»¼ ´:¹»²ò

Þ(®²æ

Ü« ³; µ«² ¹·ª» Ý®»±² ïðòððð »²¬»®±µ¿°-´»® ¬·´ ¾(®² «²¼»® ïë ;® »º¬»® ´:¹»²-

¿²ª·-²·²¹ò

Ü« µ¿² -§²µ» µ¿°-´»®²» ¸»´»ô »´´»® ¼« µ¿² ;¾²» ¼»³ô ±¹ ¾®«¹» ¹®¿²«´¿¬»¬ -±³

¼®§- °; ºò»µ-ò §³»®ò Ü»¬ »® ª·¹¬·¹¬ ¿¬ ·²¼¬¿¹» ¹®¿²«´¿¬»¬ ÍÌÎßÕÍ »º¬»® ¿¬ ¼« ¸¿®

¾´¿²¼»¬ ¼»¬ò Ù®¿²«´¿¬»¬ ³; ×ÕÕÛ ¬§¹¹»-ò

ײ¼¬¿¹ ¿´¬·¼ ®·¹»´·¹ ª:-µ» øî Š í ´·¬»®÷ ¸ª»® ¼¿¹ · ¼» °»®·±¼»®ô ¸ª±® ¼« ¾®«¹»®

Ý®»±² ïðòðððò

Z²¼®·²¹ »´´»® -¬±° · ¾»¸¿²¼´·²¹»² ¾(® µ«² -µ» · -¿³®;¼ ³»¼ ´:¹»²ò

Ø¿® ¼« ¬¿¹»¬ º±® ³»¹»¬ Ý®»±² ïðòðððá

Õ±²¬¿µ¬ ´:¹»²ô -µ¿¼»-¬«»² »´´»® ¿°±¬»µ»¬ô ¸ª·- ¼« ¸¿® ¬¿¹»¬ ³»®» ¿º Ý®»±²

ïðòðððô »²¼ ¼»® -¬;® · ¼»²²» ·²º±®³¿¬·±²ô »´´»® ³»®» »²¼ ´:¹»² ¸¿® º±®»-µ®»ª»¬ô

±¹ ¼« º(´»® ¼·¹ «¬·´°¿-ò

п

¸;®¼» »²¬»®±µ¿°-´»®

ïðìðìçë

Ø¿® ¼« ¹´»³¬ ¿¬ ¬¿¹» Ý®»±² ïðòðððá

Ù´»³³»® ¼« ¿¬ ¬¿¹» »² ¼±-·-ô -; ¬¿¹ ¼»² · º±®¾·²¼»´-» ³»¼ ²:-¬» ³;´¬·¼ò Ì¿¹

¿´¼®·¹ ¼±¾¾»´¬ ¼±-·-ò

ìò Þ×Ê×ÎÕÒ×ÒÙÛÎ

Ý®»±² ïðòðð𠵿² -±³ ¿´ ¿²¼»² ³»¼·½·² ¹·ª» ¾·ª·®µ²·²¹»®ò

ß´ª±®´·¹» ¾·ª·®µ²·²¹»®æ

Ó»¹»¬

-¶:´¼²»

¾·ª·®µ²·²¹»®

ø¼»¬

º±®»µ±³³»®

¸±-

º:®®»

»²¼

«¼

¿º

ïðòððð °¿¬·»²¬»®÷æ

Þ·²¼»ª:ª-º±®¿²¼®·²¹»®

¬§µ¬¿®³»²ò

Ú±®-²:ª®·²¹»®

¿º

¬§µ¬¿®³»² ±¹ ¾´±¼ · ¿ºº(®·²¹»²ò

×µµ» ¿´ª±®´·¹» ¾·ª·®µ²·²¹»®æ

ß´³·²¼»´·¹»

¾·ª·®µ²·²¹»®

ø¼»¬

º±®»µ±³³»®

¸±-

³»´´»³

±¹

ïð

«¼

¿º

ïðð °¿¬·»²¬»®÷æ Ó¿ª»-³»®¬»®ò

×µµ» ¿´³·²¼»´·¹» ¾·ª·®µ²·²¹»® ø¼»¬ º±®»µ±³³»® ¸±- ³»´´»³ ï ±¹ ïð «¼ ¿º

ïòððð °¿¬·»²¬»®÷æ Ü·¿®7ô µª¿´³»ô º±®-¬±°°»´-»ô ±°µ¿-¬²·²¹ô «²±®³¿´ ¿ºº(®·²¹ ±¹

«¼-´:¬ò

Ú®»µª»²- «µ»²¼¬æ Ê:¹¬¬¿¾ô ·®®·¬¿¬·±² ª»¼ »²¼»¬¿®³»² ±¹ ´«º¬ · ³¿ª»²ò

Ú±®¬:´ ´:¹» »´´»® ¿°±¬»µô ¸ª·- ¼« º;® ¿²¼®» ¾·ª·®µ²·²¹»® »²¼ ¼»³ô ¼»® -¬;® ¸»® ·

·²º±®³¿¬·±²»²ô -; ¾·ª·®µ²·²¹»®²» µ¿² ¾´·ª» ·²¼¾»®»¬¬»¬ ¬·´ Ô:¹»³·¼¼»´-¬§®»´-»²ô

±¹ ª·¼»² ±³ ¾·ª·®µ²·²¹»® µ¿² ¾´·ª» ¾»¼®»ò

Ú±®¬:´

´:¹»

»´´»®

¿°±¬»µô

¸ª·-

¼«

º;®

¾·ª·®µ²·²¹»®ô ¼»®

¾´·ª»®

ª»¼

±¹

»®

¹»²»®»²¼»ò Ò±¹´» ¾·ª·®µ²·²¹»® µ¿² µ®:ª» ¾»¸¿²¼´·²¹ò

п¬·»²¬»®

»´´»®

°;®(®»²¼»

µ¿²

±¹-;

·²¼¾»®»¬¬»

¾·ª·®µ²·²¹»®

¼·®»µ¬»

¬·´

Ô:¹»³·¼¼»´-¬§®»´-»²ò

²»¬-¬»¼æ ©©©ò´¿»¹»³·¼¼»´-¬§®»´-»²ò¼µ

ëò ÑÐÞÛÊßÎ×ÒÙ

Ñ°¾»ª¿® Ý®»±² ïðòðð𠫬·´¹:²¹»´·¹¬ º±® ¾(®²ò

Þ®«¹ ·µµ» µ¿°-´»®²»ô ¸ª·- ¼» ª·-»® ¬§¼»´·¹» ¬»¹² °; º±®¼:®ªò

Þ®«¹ ·µµ» Ý®»±² ïðòðð𠻺¬»® ¼»² «¼´(¾-¼¿¬±ô ¼»® -¬;® °; °¿µ²·²¹»²ò

êò ÇÜÛÎÔ×ÙÛÎÛ ×ÒÚÑÎÓßÌ×ÑÒ

Ý®»±² ïðòððð ·²¼»¸±´¼»®æ

Ý®»±² ïðòððð ¸;®¼» »²¬»®±µ¿°-´»®

Ü»¬ ¿µ¬·ª» ·²¼¸±´¼--¬±º · Ý®»±² ïðòððð »® °¿²µ®»¿¬·² -ª¿®»²¼» ¬·´

ß³§´¿-»

èòððð ÛÐ󻲸»¼»®

Ô·°¿-»

ïðòððð ÛÐ󻲸»¼»®

Ю±¬»¿-»

êðð ÛÐ󻲸»¼»®

ض:´°»-¬±ºº»®²»

»®æ

Ó¿½®±¹±´

ìðððå

¸§°®±³»´´±-»°¸¬¸¿´¿¬å

½»¬§´

¿´µ±¸±´å

¬®·»¬¸§´½·¬®¿¬å ¼·³»¬·½±²ò

Ù»´¿¬·²»µ¿°-´»² »® º¿®ª»¬ ³»¼ ¹«´ô ®(¼ ±¹ -±®¬ ¶»®²±¨·¼ øÛïéî÷ ±¹ ¬·¬¿²¼·±¨·¼

øÛïéï÷ ±¹ ·²¼»¸±´¼»® ²¿¬®·«³´¿«®§´-«´°¸¿¬ò

Ý®»±² ïðòððð »²¬»®±µ¿°-´»® »® -«µµ»®ó ±¹ ´¿½¬±-»º®·ò

Ó¿®µ»¼-º(®·²¹ · Ü¿²³¿®µæ

ͱ´ª¿§ и¿®³¿½»«¬·½¿´- Ù³¾Ø

Ø¿²-óÞ*½µ´»®óß´´»» îð i Üóíðïéí Ø¿²²±ª»® i ̧-µ´¿²¼

λ°®:-»²¬¿²¬ · Ü¿²³¿®µæ

ͱ´ª¿§ и¿®³¿ ßÐÍ

Ø(®µ:® îè i ÜÕóîéíð Ø»®´»ª

Ú®»³-¬·´´»®æ

ͱ´ª¿§ и¿®³¿½»«¬·½¿´- Ù³¾Ø

Ö«-¬«-󪱲óÔ·»¾·¹óͬ®¿--» íí i Üóíïëíë Ò»«-¬¿¼¬ i ̧-µ´¿²¼

λª·¼»®»¬ ³¿®¬- îððé

18-2-2019

Meer BIG-registraties verpleegkundigen, fysiotherapeuten en verloskundigen

Meer BIG-registraties verpleegkundigen, fysiotherapeuten en verloskundigen

Het aantal zorgverleners met een BIG-registratie in de beroepen verpleging, fysiotherapie en verloskunde is de afgelopen jaren gestaag gestegen. Dat meldt minister Bruno Bruins voor Medische Zorg en Sport in een brief aan de Tweede Kamer. In de periode 2014-2018 waren er in deze beroepen bijna 47.000 nieuwe registraties in het BIG-register. Daar stonden 33.350 doorhalingen tegenover van zorgverleners die niet opnieuw geregistreerd konden of wilden worden. De netto stijging komt daarmee op 13.650 geregist...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

15-2-2019

Toegang tot Wet langdurige zorg ook voor mensen met een psychische stoornis

Toegang tot Wet langdurige zorg ook voor mensen met een psychische stoornis

Mensen die hun leven lang intensieve geestelijke gezondheidszorg (GGZ) nodig hebben, kunnen vanaf 2021 toegang krijgen tot de Wet langdurige zorg (Wlz). Het gaat hierbij naar verwachting om 10.000 cliënten die permanent toezicht of 24 uur per dag zorg in de nabijheid nodig hebben en nu zorg en ondersteuning krijgen vanuit de Wet maatschappelijk ondersteuning of de Zorgverzekeringswet. De ministerraad heeft op voorstel van staatssecretaris Blokhuis van Volksgezondheid, Welzijn en Sport ingestemd met toeze...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

15-2-2019

Safety of Yarrowia lipolytica yeast biomass as a novel food pursuant to Regulation (EU) 2015/2283

Safety of Yarrowia lipolytica yeast biomass as a novel food pursuant to Regulation (EU) 2015/2283

Published on: Thu, 14 Feb 2019 Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver a scientific opinion on Yarrowia lipolytica yeast biomass as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is the dried and heat‐killed biomass of Yarrowia lipolytica, a yeast species that is widespread in nature and which can be found in the environment as well as in foods. The production process is sufficiently describ...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-2-2019

Health Canada will be updating its safety review of breast implants

Health Canada will be updating its safety review of breast implants

OTTAWA - Health Canada will be updating its safety review of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) following an increase in reports of Canadian cases. As of January 1, 2019, Health Canada has received reports of 22 confirmed and 22 suspected Canadian cases of BIA-ALCL. In its initial safety review in 2017, Health Canada found that the rate of BIA-ALCL cases was low, with 5 confirmed Canadian cases of BIA-ALCL reported by Canadian manufacturers in the last 10 years. Increased...

Health Canada

9-2-2019

Birdseed Food Co. Issues Allergy Alert on Undeclared Cashews in Craft Granola Goldenola Turmeric & Ginger

Birdseed Food Co. Issues Allergy Alert on Undeclared Cashews in Craft Granola Goldenola Turmeric & Ginger

BIRDSEED FOOD CO. of Bend, OR is recalling Craft Granola Goldenola Turmeric & Ginger that was sold between the dates of 10/03/18 - 02/07/19, because it contains undeclared cashews. People who have an allergy or severe sensitivity to cashews run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

26-1-2019

Scientific Opinion on Flavouring Group Evaluation 217 Revision 2 (FGE.217Rev2), consideration of genotoxic potential for α,β‐unsaturated ketones and precursors from chemical subgroup 4.1 of FGE.19: lactones

Scientific Opinion on Flavouring Group Evaluation 217 Revision 2 (FGE.217Rev2), consideration of genotoxic potential for α,β‐unsaturated ketones and precursors from chemical subgroup 4.1 of FGE.19: lactones

Published on: Fri, 25 Jan 2019 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 12 flavouring substances from subgroup 4.1 of FGE.19 in the Flavouring Group Evaluation 217 (FGE.217). Based on experimental data, in previous versions of this FGE (FGE.217 and FGE217Rev1), for 6‐methylcoumarin [FL‐no: 13.012] and 5‐ethyl‐3‐hydroxy‐4‐methylfuran‐2(5H)‐one [FL‐no: 10.023] the concern for genotoxicity was ruled out. 6‐Methylc...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP

Torrent Pharmaceuticals Limited is expanding its voluntary recall from 10 lots of Losartan potassium tablets USP to include 6 lots of Losartan potassium and hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited.

FDA - U.S. Food and Drug Administration

18-1-2019

34 nieuwe maatschappelijke diensttijdprojecten van start

34 nieuwe maatschappelijke diensttijdprojecten van start

Vandaag hebben 34 nieuwe maatschappelijke diensttijdprojecten door heel Nederland bericht gekregen dat ze financiering krijgen en van start kunnen gaan. In de maatschappelijke diensttijd krijgen jongeren de mogelijkheid om hun eigen talenten te ontdekken en ontwikkelen tijdens een periode waarin ze zich vrijwillig inzetten voor een ander of voor de samenleving. Bij de nieuwe projecten kunnen jongeren hun talenten inzetten op terreinen als media, cultuur en musea, onderwijs, techniek en ICT, zorg en klima...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

17-1-2019

Safety of cassia gum as a feed additive for cats and dogs based on a dossier submitted by Glycomer GmbH

Safety of cassia gum as a feed additive for cats and dogs based on a dossier submitted by Glycomer GmbH

Published on: Wed, 16 Jan 2019 The additive cassia gum consists mainly of high-molecular weight polysaccharides composed primarily of a linear chain of 1,4-b-D-mannopyranose units with 1,6-linked a-D-galactopyranose units. In 2014, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) delivered an opinion on the safety and efficacy of cassia gum in cats and dogs. The Panel concluded, based on positive findings observed in a bacterial reverse mutation test with a semi-refined cassia...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Safety and efficacy of benzoic acid as a technological feed additive for weaned piglets and pigs for fattening

Safety and efficacy of benzoic acid as a technological feed additive for weaned piglets and pigs for fattening

Published on: Wed, 16 Jan 2019 The additive under assessment is pure benzoic acid (> 99.8%), manufactured in the form of flakes. It is intended to be used as a technological feed additive (acidity regulator) in feedingstuffs for weaned piglets and pigs for fattening, with maximum contents of 5,000 and 10,000 mg/kg complete feed, respectively. Benzoic acid is safe for weaned piglets at 5,000 mg/kg complete feed, and at 10,000 mg/kg complete feed for pigs for fattening. The use of benzoic acid in feedings...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Safety and efficacy of 3‐phytase FSF10000 as a feed additive for chickens for fattening or reared for laying, laying hens and minor poultry species

Safety and efficacy of 3‐phytase FSF10000 as a feed additive for chickens for fattening or reared for laying, laying hens and minor poultry species

Published on: Tue, 15 Jan 2019 The additive 3‐phytase FSF10000 is a solid product that contains a 3‐phytase produced by a genetically modified strain of Komagataella phaffii. A liquid formulation of the additive has been previously assessed by the EFSA Panel on Additives and Products of Substances used in Animal Feed (FEEDAP) and is currently authorised as a feed additive for poultry species. The applicant requested for the use of this new formulation of the additive in chickens for fattening or reared ...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Published on: Fri, 11 Jan 2019 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the application for renewal of authorisation of organic form of selenium produced by Saccharomyces cerevisiae NCYC R397 (Alkosel®) for all animal species. The FEEDAP Panel has delivered two opinions (on 2007 and 2016) on the safety and efficacy of the additive. The additive is characterised as organic selenium mainly selenomethionine (63%); it was ini...

Europe - EFSA - European Food Safety Authority EFSA Journal

9-1-2019

Minister Bruno Bruins verwelkomt EMA in Nederland

Minister Bruno Bruins verwelkomt EMA in Nederland

De tijdelijke huisvesting voor het Europees Geneesmiddelen Agentschap (EMA) is klaar voor gebruik. Dit is een belangrijke stap in de verhuizing van het EMA naar Nederland. Het EMA brengt jaarlijks 36.000 bezoekers naar Nederland en zorgt voor de komst van vele bedrijven. Vandaag heeft minister Bruins de sleutel van het Spark-gebouw overgedragen aan EMA.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

8-1-2019

Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass

Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass

Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. is voluntarily recalling three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder), and one lot of Vecuronium Bromide for Injection, 20 mg (lyophilized powder) to the hospital level. The Vecuronium Bromide for Injection has been found to contain particulate matter identified as glass.

FDA - U.S. Food and Drug Administration

6-1-2019

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Lupin Pharmaceuticals, Inc. is voluntarily recalling 5 lots of Ceftriaxone for Injection, USP, 250mg, 10 lots of Ceftriaxone for Injection, USP, 500mg, 24 lots of Ceftriaxone for Injection, USP, 1g and 3 lots of Ceftriaxone for Injection, USP 2g, to the hospital/physician level. The products have been found to contain visual grey particulate matter in reconstituted vials.

FDA - U.S. Food and Drug Administration

4-1-2019

Olde York Potato Chips Issues Allergy Alert on Undeclared Milk in One Lot of Clancy's Wavy Potato Chips 10 Oz

Olde York Potato Chips Issues Allergy Alert on Undeclared Milk in One Lot of Clancy's Wavy Potato Chips 10 Oz

Olde York Potato Chips of Brampton, Ontario is recalling Clancy's Wavy Potato Chips 10 oz (UPC 0 41498 16306 8) with the specific lot code BEST If Used By FEB 22 19 1A6 because they may contain undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume these products. No other lot codes and no other products are involved in this action.

FDA - U.S. Food and Drug Administration

3-1-2019

Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP

Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP

Torrent Pharmaceuticals Limited is expanding its voluntary recall from 2 lots of Losartan potassium tablets USP to a total of 10 lots, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. Torrent is only recalling lots of losartan-containing products that contain N-nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA.

FDA - U.S. Food and Drug Administration

21-12-2018

Funky Chunky, Llc Issues Allergy Alert on Undeclared Almond and Cashew Tree-Nut in 10 Oz. Nutty Choco Pop Found in Chocolate Popcorn Gift Box, Holiday Crowd Pleaser and Crowd Pleaser Gifts

Funky Chunky, Llc Issues Allergy Alert on Undeclared Almond and Cashew Tree-Nut in 10 Oz. Nutty Choco Pop Found in Chocolate Popcorn Gift Box, Holiday Crowd Pleaser and Crowd Pleaser Gifts

Funky Chunky, LLC of Eden Prairie, MN is recalling 10 oz Nutty Choco Pop Gift Box, 50 oz. Holiday Crowd Pleaser and 50 oz. Crowd Pleaser, because it may contain undeclared Almond and Cashew Tree Nut. People who have an allergy or severe sensitivity to Almonds and Cashews run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

21-12-2018

One lot of Equate brand Lens Care System and Multi-Purpose Solution voluntarily recalled because of a labelling error

One lot of Equate brand Lens Care System and Multi-Purpose Solution voluntarily recalled because of a labelling error

Teva Canada is voluntarily recalling one lot (Lot 150261) of two products because of a labelling error. While the outer carton of Equate brand Lens Care System is correctly labelled, the bottle within the carton is mislabelled as Equate brand Multi-Purpose Solution. Because of the labelling error, the company is recalling both products labelled with Lot 150261. Bottles labelled as Equate Multi-Purpose Solution should contain a 0.0001% w/v polyhexanide based disinfecting solution for rinsing. The mislabel...

Health Canada

20-12-2018

New report on adverse reactions reported with tramadol for pain relief

New report on adverse reactions reported with tramadol for pain relief

The Danish Medicines Agency has received 830 reports of suspected adverse reactions with tramadol since the medicine was marketed in March 1993. 155 of them describe symptoms of dependence. This follows from a report that has just been published. In 2017, about 265,000 individuals received treatment with tramadol in Denmark.

Danish Medicines Agency

17-12-2018

Blokhuis stelt prioriteiten van actieprogramma Zwerfjongeren vast

Blokhuis stelt prioriteiten van actieprogramma Zwerfjongeren vast

Een betaalbare woonplek, voldoende kansen op een opleiding en een baan, financiële zelfredzaamheid en voldoende zorg en ondersteuning. Basisbehoeften voor ieder mens, maar waaraan de 10.700 zwerfjongeren (18 – 27 jaar) in Nederland nog te vaak tekortkomen. Op die vier ‘levensbrede’ prioriteiten zal de staatssecretaris zich richten met zijn actieprogramma Zwerfjongeren, dat hij afgelopen oktober in Tweede Kamer aankondigde. Met het actieprogramma brengt hij lokale partijen en gemeenten, maar ook andere ve...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

17-12-2018


Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance

Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance

Draft ezetimibe tablet 10 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

14-12-2018

Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food

Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food

Published on: Thu, 13 Dec 2018 The European Commission asked EFSA for a scientific evaluation on the risks to human health related to the presence of perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in food. Regarding PFOS and PFOA occurrence, the final data set available for dietary exposure assessment contained a total of 20,019 analytical results (PFOS n = 10,191 and PFOA n = 9,828). There were large differences between upper and lower bound exposure due to analytical methods with i...

Europe - EFSA - European Food Safety Authority Publications

12-12-2018

December 10, 2018: Olympus Medical Systems Corporation, Former Senior Executive Plead Guilty to Distributing Endoscopes After Failing to File FDA-Required Adverse Event Reports of Serious Infections

December 10, 2018: Olympus Medical Systems Corporation, Former Senior Executive Plead Guilty to Distributing Endoscopes After Failing to File FDA-Required Adverse Event Reports of Serious Infections

December 10, 2018: Olympus Medical Systems Corporation, Former Senior Executive Plead Guilty to Distributing Endoscopes After Failing to File FDA-Required Adverse Event Reports of Serious Infections

FDA - U.S. Food and Drug Administration

11-12-2018


The new EudraVigilance system and the electronic reporting of individual case safety reports in the ISO/ICH E2B(R3) format: Hands-on training course, Amsterdam, The Netherlands, from 08/04/2019 to 10/04/2019

The new EudraVigilance system and the electronic reporting of individual case safety reports in the ISO/ICH E2B(R3) format: Hands-on training course, Amsterdam, The Netherlands, from 08/04/2019 to 10/04/2019

The new EudraVigilance system and the electronic reporting of individual case safety reports in the ISO/ICH E2B(R3) format: Hands-on training course, Amsterdam, The Netherlands, from 08/04/2019 to 10/04/2019

Europe - EMA - European Medicines Agency

10-12-2018


Agenda - CHMP agenda of the 10-13 December 2018

Agenda - CHMP agenda of the 10-13 December 2018

Agenda - CHMP agenda of the 10-13 December 2018

Europe - EMA - European Medicines Agency

15-2-2019

tacrolimus (systemic formulations)

tacrolimus (systemic formulations)

tacrolimus (systemic formulations) (Active substance: tacrolimus) - Centralised - Art 28 - (PSUR - Commission Decision (2019)1437 of Fri, 15 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/00002839/201803

Europe -DG Health and Food Safety

13-2-2019


Orphan designation: P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide, Treatment of acute myeloid leukaemia, 14/10/2016, Positive

Orphan designation: P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide, Treatment of acute myeloid leukaemia, 14/10/2016, Positive

Orphan designation: P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide, Treatment of acute myeloid leukaemia, 14/10/2016, Positive

Europe - EMA - European Medicines Agency

13-2-2019


Orphan designation: Seladelpar, Treatment of primary biliary cholangitis, 16/10/2017, Positive

Orphan designation: Seladelpar, Treatment of primary biliary cholangitis, 16/10/2017, Positive

Orphan designation: Seladelpar, Treatment of primary biliary cholangitis, 16/10/2017, Positive

Europe - EMA - European Medicines Agency

28-1-2019


Tenoxicam: List of nationally authorised medicinal products - PSUSA/00002893/201802

Tenoxicam: List of nationally authorised medicinal products - PSUSA/00002893/201802

Tenoxicam: List of nationally authorised medicinal products - PSUSA/00002893/201802

Europe - EMA - European Medicines Agency

28-1-2019

Clomicalm (Elanco GmbH)

Clomicalm (Elanco GmbH)

Clomicalm (Active substance: Clomipramine hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)720 of Mon, 28 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/000039/T/0030

Europe -DG Health and Food Safety

28-1-2019


Orphan designation: Mogamulizumab, Treatment of cutaneous T-cell lymphoma, 14/10/2016, Positive

Orphan designation: Mogamulizumab, Treatment of cutaneous T-cell lymphoma, 14/10/2016, Positive

Orphan designation: Mogamulizumab, Treatment of cutaneous T-cell lymphoma, 14/10/2016, Positive

Europe - EMA - European Medicines Agency

25-1-2019


Orphan designation: Glucagon, Treatment of congenital hyperinsulinism, 08/10/2009, Positive

Orphan designation: Glucagon, Treatment of congenital hyperinsulinism, 08/10/2009, Positive

Orphan designation: Glucagon, Treatment of congenital hyperinsulinism, 08/10/2009, Positive

Europe - EMA - European Medicines Agency

24-1-2019


Treprostinil: List of nationally authorised medicinal products - PSUSA/00003013/201805

Treprostinil: List of nationally authorised medicinal products - PSUSA/00003013/201805

Treprostinil: List of nationally authorised medicinal products - PSUSA/00003013/201805

Europe - EMA - European Medicines Agency

23-1-2019

EU/3/10/777 (Voisin Consulting S.A.R.L.)

EU/3/10/777 (Voisin Consulting S.A.R.L.)

EU/3/10/777 (Active substance: Cyclic pyranopterin monophosphate) - Transfer of orphan designation - Commission Decision (2019)574 of Wed, 23 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003164

Europe -DG Health and Food Safety

23-1-2019


Terlipressin: List of nationally authorised medicinal products - PSUSA/00002905/201804

Terlipressin: List of nationally authorised medicinal products - PSUSA/00002905/201804

Terlipressin: List of nationally authorised medicinal products - PSUSA/00002905/201804

Europe - EMA - European Medicines Agency

23-1-2019


Thiamphenicol: List of nationally authorised medicinal products  - PSUSA/00002925/201805

Thiamphenicol: List of nationally authorised medicinal products - PSUSA/00002925/201805

Thiamphenicol: List of nationally authorised medicinal products - PSUSA/00002925/201805

Europe - EMA - European Medicines Agency

23-1-2019


Tafluprost: List of nationally authorised medicinal products - PSUSA/00002843/201804

Tafluprost: List of nationally authorised medicinal products - PSUSA/00002843/201804

Tafluprost: List of nationally authorised medicinal products - PSUSA/00002843/201804

Europe - EMA - European Medicines Agency

22-1-2019

EU/3/10/841 (Vanda Pharmaceuticals Germany GmbH)

EU/3/10/841 (Vanda Pharmaceuticals Germany GmbH)

EU/3/10/841 (Active substance: Tasimelteon) - Transfer of orphan designation - Commission Decision (2019)573 of Tue, 22 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002557

Europe -DG Health and Food Safety

16-1-2019

EU/3/10/833 (FGK Representative Service GmbH)

EU/3/10/833 (FGK Representative Service GmbH)

EU/3/10/833 (Active substance: Doxorubicin hydrochloride (in heat-sensitive liposomes)) - Transfer of orphan designation - Commission Decision (2019)237 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003113

Europe -DG Health and Food Safety

11-1-2019


Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Orphan designation: 6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate, Treatment of cystic fibrosis, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant, Treatment of haemophilia B, 26/10/2018, Positive

Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant, Treatment of haemophilia B, 26/10/2018, Positive

Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant, Treatment of haemophilia B, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

11-1-2019


Orphan designation: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, Treatment of medullary thyroid carcinoma, 26/10/2018, Positive

Orphan designation: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, Treatment of medullary thyroid carcinoma, 26/10/2018, Positive

Orphan designation: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, Treatment of medullary thyroid carcinoma, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Orphan designation: autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA, Treatment of mucopolysaccharidosis type I, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII, Treatment of haemophilia

Orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII, Treatment of haemophilia

Orphan designation: Recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII, Treatment of haemophilia A, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment

Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment

Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment of maple syrup urine disease, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: gefinitib, Treatment of Fanconi anaemia type A, 26/10/2018, Positive

Orphan designation: gefinitib, Treatment of Fanconi anaemia type A, 26/10/2018, Positive

Orphan designation: gefinitib, Treatment of Fanconi anaemia type A, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019


Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Orphan designation: Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG, Treatment of multiple myeloma, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

10-1-2019

Strensiq (Alexion Europe SAS)

Strensiq (Alexion Europe SAS)

Strensiq (Active substance: asfotase alfa) - Centralised - Yearly update - Commission Decision (2019)69 of Thu, 10 Jan 2019

Europe -DG Health and Food Safety

4-1-2019


Orphan designation: avapritinib, Treatment of mastocytosis, 26/10/2018, Positive

Orphan designation: avapritinib, Treatment of mastocytosis, 26/10/2018, Positive

Orphan designation: avapritinib, Treatment of mastocytosis, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

19-12-2018


Orphan designation: melatonin, Treatment of acute radiation syndrome, 26/10/2018, Positive

Orphan designation: melatonin, Treatment of acute radiation syndrome, 26/10/2018, Positive

Orphan designation: melatonin, Treatment of acute radiation syndrome, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

19-12-2018


Recommendations on eligibility to PRIME scheme -  Adopted at the CHMP meeting of 10-13 December 2018

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 December 2018

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 December 2018

Europe - EMA - European Medicines Agency

14-12-2018


Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018

Europe - EMA - European Medicines Agency

10-12-2018

Exondys (AVI BioPharma International Ltd)

Exondys (AVI BioPharma International Ltd)

Exondys (Active substance: eteplirsen) - Centralised - Refusal of marketing authorisation - Commission Decision (2018)8620 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4355

Europe -DG Health and Food Safety

10-12-2018

Ivabradine JensonR (JensonR+ Limited)

Ivabradine JensonR (JensonR+ Limited)

Ivabradine JensonR (Active substance: ivabradine) - Centralised - Withdrawal - Commission Decision (2018)8623 of Mon, 10 Dec 2018

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1662 (QRC Ireland)

EU/3/16/1662 (QRC Ireland)

EU/3/16/1662 (Active substance: H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate) - Transfer of orphan designation - Commission Decision (2018)8626 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/011/16/T/01

Europe -DG Health and Food Safety

10-12-2018

EU/3/17/1906 (PTC Therapeutics International Limited)

EU/3/17/1906 (PTC Therapeutics International Limited)

EU/3/17/1906 (Active substance: Recombinant adeno-associated viral vector serotype 5 carrying the gene for the human frataxin protein) - Transfer of orphan designation - Commission Decision (2018)8634 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002509

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1786 (PTC Therapeutics International Limited)

EU/3/16/1786 (PTC Therapeutics International Limited)

EU/3/16/1786 (Active substance: Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein) - Transfer of orphan designation - Commission Decision (2018)8630 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002507

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1651 (PTC Therapeutics International Limited)

EU/3/16/1651 (PTC Therapeutics International Limited)

EU/3/16/1651 (Active substance: Recombinant adeno-associated viral vector serotype 9 carrying the gene for the human E6-AP ubiquitin protein ligase) - Transfer of orphan designation - Commission Decision (2018)8632 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002508

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1802 (FGK Representative Service GmbH)

EU/3/16/1802 (FGK Representative Service GmbH)

EU/3/16/1802 (Active substance: Ivosidenib) - Transfer of orphan designation - Commission Decision (2018)8627 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002422

Europe -DG Health and Food Safety

10-12-2018

EU/3/10/760 (TESARO Bio Netherlands B.V.)

EU/3/10/760 (TESARO Bio Netherlands B.V.)

EU/3/10/760 (Active substance: (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt) - Transfer of orphan designation - Commission Decision (2018)8636 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002385

Europe -DG Health and Food Safety

10-12-2018

EU/3/17/1893 (SFL Regulatory Services GmbH)

EU/3/17/1893 (SFL Regulatory Services GmbH)

EU/3/17/1893 (Active substance: Polyphenyl(disodium 3-O-sulfo-beta-D-glucopyranuronate)-(1?3)-beta-D-galactopyranoside) - Transfer of orphan designation - Commission Decision (2018)8628 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/048/17/T/01

Europe -DG Health and Food Safety

10-12-2018

EU/3/09/628 (Nova Laboratories Ireland Limited)

EU/3/09/628 (Nova Laboratories Ireland Limited)

EU/3/09/628 (Active substance: Mercaptopurine (oral suspension)) - Transfer of orphan designation - Commission Decision (2018)8629 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002301

Europe -DG Health and Food Safety